Alcon Announces Acquisition of Tear Film Innovations, Inc. - Seite 2

"Since launching the iLux Device earlier this year, we've seen an enthusiastic response from eye care professionals who have already begun to incorporate it as an advanced treatment option for patients suffering from Meibomian Gland Dysfunction," said Rob Thornhill, CEO of Tear Film. "Now, as part of Alcon, we're eager to bring this technology to even more offices throughout the world."

The iLux Device is currently available in the U.S. and Canada. Alcon expects to announce plans to expand to other countries in 2019.


Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 that can generally be identified by words such as "plans," "in early 2019," "portfolio," "committed," "launched," "launching," "enthusiastic response," "eager," "later next year," "expects," "will," "potential," or similar expressions, or by express or implied discussions regarding the potential impact on Novartis or Alcon of the acquisition of Tear Film, including express or implied discussions regarding potential future sales or earnings of Novartis and Alcon, and any potential strategic benefits, synergies or opportunities expected as a result of the acquisition; or regarding potential additional marketing submissions or approvals for the iLux Device, potential expanded availability of the iLux Device, potential commercial success of the iLux Device, and potential future revenues from the iLux Device.  Such forward looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward looking statements. You should not place undue reliance on these statements. In particular, our expectations could be affected by, among other things: regulatory actions or delays or government regulation generally, including potential regulatory actions or delays relating with respect to the iLux Device; the potential that the strategic benefits, synergies or opportunities expected from the proposed acquisition may not be realized or may take longer to realize than expected; the uncertainties inherent in the research and development, including clinical trial results and additional analysis of existing clinical data; our ability to obtain or maintain proprietary intellectual property protection; the ability of Alcon to successfully promote and expand access to the iLux Device; safety, quality or manufacturing issues; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures; the particular preferences of physicians and patients; and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission (SEC) or in the initial Form 20-F filed by Alcon with the SEC. Novartis and Alcon are providing the information in this press release as of this date and do not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.